Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 11/20 | 0.45 |
| ▸ | THRB | P10828 | 11/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140412 | 1.00 | THRA (0.45) | THRATHRBNPSR1PPARGPPARA | |
| Alanine SCHEMBL5073607 | 0.81 | THRB (0.41) | THRATHRBGRM4 | |
| Alanine SCHEMBL5073599 | 0.81 | THRB (0.41) | THRATHRBGRM4 | |
| SCHEMBL3137311 | 0.81 | THRB (0.42) | THRATHRB | |
| SCHEMBL5073611 | 0.77 | GRM4 (0.34) | THRATHRBGRM4 | |
| SCHEMBL4356925 | 0.76 | THRA (0.74) | THRATHRB | |
| SCHEMBL5619344 | 0.76 | THRA (0.74) | THRATHRB | |
| SCHEMBL3131333 | 0.75 | THRA (0.39) | THRATHRBPPARGGRM4 | |
| SCHEMBL3140469 | 0.74 | THRA (0.43) | THRATHRB | |
| SCHEMBL3140462 | 0.74 | THRA (0.43) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | THRA 3916/4885THRB 2897/4885NPSR1 2567/4885 |
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | THRA 4/4885THRB 6/4885NPSR1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.